0.04
+100.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nymox Pharmaceutical
Its shares trade under the ticker NYMXF. It has been listed since 26 November 1997. In the fiscal year to 31 December 2020, it reported revenue of $10,000 and a net loss of $11.7m. At that date it held total assets of $4.3m and shareholders' equity of $2.1m.
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The firm operates through the research and development of products for the aging population segment. The firm markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The firm also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The firm also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The firm's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Nov 1997
- Employees
- 3
- Website
- nymox.com ↗
- Head office
- 9900 CAVENDISH BLVD., SUITE 306, QUEBEC CANADA, A8, H4M 2V2
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Paul AverbackCo-Chairman of the Board, President, Chief Executive Officer, since 1995$157,000
- Mr. James RobinsonIndependent Co-Chairman of the Board$100,000
- Mr. Patrick DoodyVice President, General Counsel$1.1m
- Prof. Dr. David MorseIndependent Director$50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 44
- Social
- 65
- Governance
- 21
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Extensive experience in the pharmaceutical industry.
- Strong portfolio of patented products.
- Robust research and development capabilities.
Weaknesses
- Limited financial resources compared to larger competitors.
- Relatively small market share in some key therapeutic areas.
- Dependence on limited number of drug candidates in development.
Opportunities
- Increasing demand for innovative pharmaceutical solutions.
- Growing healthcare market, particularly in emerging economies.
- Potential partnerships with larger pharmaceutical companies.
Threats
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements for drug approval.
- Potential disruption in supply chains due to global events.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.